Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 #COVID19Vaccines in US Children Aged 6 Months to 17 Years | Pediatrics | JAMA Network Open | JAMA Network https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2818033#Myocarditis and #pericarditis are rare events, with a reported mean incidence of 39.3 cases per 1 million vaccine doses administered in children aged 5 to 17 years within 7 days after BNT162b2 vaccination. (1/3)
Safety of Ancestral Monovalent COVID-19 Vaccines in US Children

This cohort study examines prespecified health outcomes after vaccination with an ancestral monovalent COVID-19 vaccine in US children aged 6 months to 17 years.

For the myocarditis or pericarditis outcome measured in the inpatient and emergency department settings in the 1 to 7 days after vaccinations, we observed approximately 27.0 inpatient or emergency department cases per million doses in days 1 to 7 after the primary series in children aged 12 to 15 years and 38.2 cases per million doses after the primary series in children aged 16 to 17 years. (2/3)
We did not detect a statistical signal for myocarditis or pericarditis in children younger than 12 years, which is consistent with reports from other surveillance systems.” (3/3)